Marksans Pharma Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 24	Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20

Sources of funds

Owner's fund

Equity share capital

45.32

45.32

40.93

40.93

40.93

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

1,177.39

1,066.01

743.74

558.79

464.69

Loan funds

Secured loans

-

-

5.00

-

-

Unsecured loans

-

-

-

-

-

Total

1,222.71

1,111.32

789.67

599.72

505.63

Uses of funds

Fixed assets

Gross block

419.32

264.65

234.33

224.19

196.31

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

147.75

120.71

98.81

95.11

81.13

Net block

271.58

143.94

135.51

129.09

115.18

Capital work-in-progress

-

3.91

-

-

-

Investments

292.75

266.29

236.51

236.07

236.07

Net current assets

Current assets, loans & advances

951.72

930.72

593.59

353.40

248.52

Less : current liabilities & provisions

293.33

233.54

175.94

118.84

94.15

Total net current assets

658.38

697.18

417.65

234.56

154.37

Miscellaneous expenses not written

-

-

-

-

-

Total

1,222.71

1,111.32

789.67

599.72

505.63

Notes:

Book value of unquoted investments

292.75

265.75

236.07

236.07

236.07

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

22.06

9.31

114.36

115.10

140.38

Number of equity sharesoutstanding (Lacs)

4531.64

4531.64

4093.14

4093.14

4093.14